CYBDA: CDH20124 and other new compounds are under development

On December 1, 2022, CYNDA held the company's third quarter 2022 results presentation at the Shanghai Stock Exchange by means of graphic display and web text interaction. Wang, Chairman of CYNDA and other relevant persons attended the presentation and answered the questions raised by investors. Problems in the production and operation of some pesticides are summarized as follows:

Q：The total revenue of the company in the third quarter was ¥806 million, of which the revenue of the five main products disclosed in the main operating data of the third quarter was ¥460 million.What products were responsible for the remaining ¥350 million in revenue?

A：The remaining revenue of ¥350 million in the third quarter of the company was mainly generated by domestic formulations of Oxaziclomefone   series and the created product of Quinotrione.

Q: The company's sales volume of Quinotrione has increased significantly this year. Are you considering increasing the production capacity of Quinotrione?

A: Yes, its annual sales volume has increased significantly, meeting its sales expectations, and it has considered expanding production in the fourth phase of the Liaoning Project.

Q: This year, your company's overseas pesticide sales have increased significantly. Can this growth continue next year? Can the current production capacity guarantee the growth demand of the overseas market?

A: The world's food demand is just that, and demand is growing steadily, as is the herbicide market. After the completion of Phase III and Phase V projects, the company has sufficient production capacity of main products to meet the growth demand of overseas markets.

Q: Why did the company's performance explode this year? What is your expectation for next year's performance growth?

A: The performance in 2022 increased significantly compared with that in 2021, mainly due to the release of production capacity, the increase of product price and the promotion of the company's branded products. Both overseas sales and domestic sales of formulations achieved a significant increase! In 2023, based on the existing products, we will focus on the rapid production of new capacity. At the same time, in terms of domestic marketing, we will strive to achieve a substantial increase in domestic marketing by increasing the promotion of brand products and created compounds. thank you

Q: Your company's CDH20124 has entered the development stage. When is it expected to be approved for market?

A: The company is developing several new compounds, including CDH20124, which need to be comprehensively evaluated for efficacy, safety, cost, process difficulty and toxicity before they can enter the registration channel. Thanks!

Q: Can you introduce the situation of pesticide registration abroad this year? Is the number of registrations obtained increased or decreased compared to last year.

A: In 2022, the company's products are mainly registered in Australia, the European Union, Brazil, Argentina and other countries and regions, and the number of registered products has increased significantly compared with last year. Thanks!

Q: Can you disclose the sales volume and sales value of Quinotrione by the end of the third quarter of this year? What is the unit price of sales? 

A: This year, Quinotrione is in its second year on the market and is currently in the marketing phase.